Taro Pharmaceutical Industries Ltd financial data

Industry
Pharmaceutical Preparations
Location
14 Haktor St, Haifa Bay, Israel
Fiscal year end
March 31
Latest financial report
20-F - Q1 2023 - Jun 29, 2023

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 37.6M shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 154M USD -38.5%
Marketable Securities, Current 576M USD +10.3%
Inventory, Net 227M USD +7.71%
Assets, Current 1.34B USD -0.11%
Deferred Income Tax Assets, Net 104M USD -17%
Property, Plant and Equipment, Net 190M USD -4.78%
Operating Lease, Right-of-Use Asset 3.87M USD -28.6%
Goodwill 17.2M USD +45.8%
Other Assets, Noncurrent 83.1M USD +24.3%
Assets 2.14B USD -1.88%
Accounts Payable, Current 3.65M USD +166%
Employee-related Liabilities, Current 23.1M USD -3.39%
Accrued Liabilities, Current 24M USD -4.88%
Contract with Customer, Liability, Current 903K USD -84.4%
Liabilities, Current 386M USD -10.8%
Other Liabilities, Noncurrent 19.1M USD -41.7%
Liabilities 405M USD -13%
Accumulated Other Comprehensive Income (Loss), Net of Tax -175M USD -3.57%
Retained Earnings (Accumulated Deficit) 2.41B USD +1.07%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 1.73B USD +1.13%
Liabilities and Equity 2.14B USD -1.88%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 45.1M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 22.2M USD +0.26%
Deferred Tax Assets, Gross 131M USD -14.8%
Lessee, Operating Lease, Liability, to be Paid 4.05M USD -34.3%
Property, Plant and Equipment, Gross 522M USD +2.16%
Operating Lease, Liability, Current 1.95M USD -11.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.41M USD -10.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.77M USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year Three 874K USD -32.2%
Deferred Tax Assets, Operating Loss Carryforwards 18.5M USD -50.7%
Unrecognized Tax Benefits 37.5M USD +8.43%
Additional Paid in Capital 262M USD 0%
Deferred Tax Assets, Net of Valuation Allowance 109M USD -17.4%